CSL is a large speciality biopharmaceutical company developing and manufacturing plasma products and vaccines to treat and protect patients worldwide.
Originally set up in 1916 in Australia to service the countries citizens who were impacted by the war, CSL has developed into a global vaccine specialist and now owns three major subsidiary companies which operate under the names of CSL Behring, bioCSL and CSL Pharma.
CSL Behring focuses upon the collection and delivery of plasma products whereas bioCSL is more committed to the development, investment and licensing of vaccines and anti venoms. Over the 2006/07 period CSL invested $190m in order to implement new R&D centres of excellence which develop new products and improve existing ones.
CSL’s products include immunoglobulins, haemophilia products and vaccines. The company also has a major stake in the US$2bn influenza market annually by manufacturing and delivering its globally recognized influenza vaccine to patients worldwide.
CSL functions under a set of core values which include a customer focused approach, ethical and honest conduct and working via collaborations. The company is also very established in terms of capabilities, having many of them already functioning in-house; it has a large number of its own technologies which help to support early stage technologies, it conducts clinical trials worldwide and is also very proficient in manufacturing.
Finally it is well positioned to commercialize new products and has been involved with many successful product launches to date.
This being said CSL does have a number of partnerships in place, some that focus on R&D and some that involve directly delivering life-saving products to companies around the world.
When it comes to licensing new products into the company; CSL is interested in sourcing protein-based candidates that have strong clinical data with a define mechanism of action that form some synergy with the product currently being offered by the business.
The company currently supply the following products through partnerships with countries around the world; immunogloblulins, haemophilia, speciality products and vaccines.
The different divisions of the business develop and manufacture the following products in the following therapy areas:
Plasma derived medications: bleeding disorders, infectious diseases, autoimmune diseases
Vaccines, anti-venoms, diagnostic products and pharmaceuticals
CSL is routinely present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a small amount of time.
Events with CSL presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with CSL in person visit Current Partnering’s Event calendar.
Contacting CSL for partnering
CSL can be contacting in relation to partnering through a number of channels.
Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with CSL’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Email contact to a named individual view the list of contacts at CSL’s website for details.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel. Many of CSL’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit CSL’s LinkedIn page here.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. CSL does not provide an online opportunity submission form.
Available reports from Current Partnering
Report: Partnering Deals and Alliances with CSL
Available resources for deal coverage for CSL
Read: more on CSL company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk